Denali Therapeutics Long Term Debt

Denali Therapeutics (DNLI) currently reports a long-term debt of $28M as of June 2026. That compares with $38M in the prior-year period — down 27.0% year over year. Use the charts on this page to explore Denali Therapeutics's long-term debt history and peer comparisons.

Denali Therapeutics's long-term debt decreased from $38M to $28M — a 27.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Denali Therapeutics reported $28M in long-term debt as of June 2026. That compares with $38M in the prior-year period — down 27.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $28M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Denali Therapeutics, and consider following DNLI for alerts when major investors trade the stock.

Denali Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $28M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNLI with unrelated industries.